Boehringer Ingelheim Venture Fund

The Boehringer Ingelheim Venture Fund (BIVF) invests in pioneering science that aims to redefine the standard of care and bring new medicines to patients. As a dedicated Seed/Series A investor with company formation expertise, BIVF primarily invests in pre-clinical assets and platforms. Their activities are closely aligned with Boehringer Ingelheim's strategic interests and promote fostering potential business development targets. BIVF strategically takes a minority shareholder position and requires a voting board seat to actively support their portfolio companies. BIVF aims to redefine standards of care and drive Boehringer Ingelheim's expansion into groundbreaking medical treatments. They are shaping the future of healthcare by supporting transformative areas like Cancer, Regenerative medicine, Auto-immunity, Digital solutions, and Infectious disease. Their strategic investments position BIVF as a leader in propelling innovation. Established in 2010, the BIVF is a €350M evergreen fund with a global presence in the EU, US, and China. They are committed to advancing scientific innovation by investing in first-in-class, disease-modifying therapeutics across various modalities. The fund invests in companies with groundbreaking innovation across Cancer, Regenerative medicine, Auto-immunity indications, Digital solutions, and Infectious disease. BIVF's approach includes taking minority shareholder positions, requiring a voting board seat to actively support portfolio companies, and close alignment with Boehringer Ingelheim's strategic interests, fostering potential business development targets.

Cancer (immuno-oncology & targeted therapy), Regenerative medicine (incl. cell reprogramming & neuro degeneration), Auto-immunity indications, Digital solutions (supporting the pharma value chain), Infectious disease (focus to AMR)

Core thematic spaces, technologies, and target market segments of interest.